These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9411660)

  • 21. Prevention of relapse in alcohol dependence.
    Malerich JA
    Am Fam Physician; 1999 Apr; 59(7):1753-4. PubMed ID: 10208698
    [No Abstract]   [Full Text] [Related]  

  • 22. The application of machine learning techniques as an adjunct to clinical decision making in alcohol dependence treatment.
    Connor JP; Symons M; Feeney GF; Young RM; Wiles J
    Subst Use Misuse; 2007; 42(14):2193-206. PubMed ID: 18098000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo.
    Dahl H; Hammarberg A; Franck J; Helander A
    Alcohol Alcohol; 2011; 46(5):553-7. PubMed ID: 21616946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacological treatment of alcohol dependence: needs and possibilities.
    Mann K
    Alcohol Alcohol; 1996 Mar; 31 Suppl 1():55-8. PubMed ID: 8737001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
    J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical and clinical pharmacology of alcohol dependence.
    Tambour S; Quertemont E
    Fundam Clin Pharmacol; 2007 Feb; 21(1):9-28. PubMed ID: 17227441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acamprosate and naltrexone: similar efficacy for relapse].
    Saitz R
    Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
    [No Abstract]   [Full Text] [Related]  

  • 28. From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap.
    Shea CW
    South Med J; 2008 Feb; 101(2):179-85. PubMed ID: 18364621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
    Hillemacher T; Kornhuber J; Bleich S
    Fortschr Neurol Psychiatr; 2007 Jan; 75(1):26-32. PubMed ID: 17031777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.
    Croissant B; Diehl A; Klein O; Zambrano S; Nakovics H; Heinz A; Mann K
    Alcohol Clin Exp Res; 2006 Apr; 30(4):630-5. PubMed ID: 16573580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy: what does acamprosate and naltrexone combination tell us?
    Kiefer F; Wiedemann K
    Alcohol Alcohol; 2004; 39(6):542-7. PubMed ID: 15456690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients.
    Weinstein A; Feldtkeller B; Feeney A; Lingford-Hughes A; Nutt D
    Addict Biol; 2003 Jun; 8(2):229-32. PubMed ID: 12850782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Acamprosate--a novel treatment for alcoholism].
    Golovko SI; Zefirov SIu; Golovko AI; Shpilenia LS; Nekrasov IuA
    Eksp Klin Farmakol; 2000; 63(3):70-3. PubMed ID: 10934602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial.
    Morley KC; Teesson M; Sannibale C; Baillie A; Haber PS
    Alcohol Alcohol; 2010; 45(6):520-6. PubMed ID: 20952764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
    Kiefer F; Jiménez-Arriero MA; Klein O; Diehl A; Rubio G
    Addict Biol; 2008 Mar; 13(1):124-9. PubMed ID: 17573782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
    Verheul R; Lehert P; Geerlings PJ; Koeter MW; van den Brink W
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):167-73. PubMed ID: 15322728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acamprosate and its efficacy in treating alcohol dependent adolescents.
    Niederhofer H; Staffen W
    Eur Child Adolesc Psychiatry; 2003 Jun; 12(3):144-8. PubMed ID: 12768462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does acamprosate improve reduction of drinking as well as aiding abstinence?
    Chick J; Lehert P; Landron F;
    J Psychopharmacol; 2003 Dec; 17(4):397-402. PubMed ID: 14870951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
    Kiefer F; Witt SH; Frank J; Richter A; Treutlein J; Lemenager T; Nöthen MM; Cichon S; Batra A; Berner M; Wodarz N; Zimmermann US; Spanagel R; Wiedemann K; Smolka MN; Heinz A; Rietschel M; Mann K
    Pharmacogenomics J; 2011 Oct; 11(5):368-74. PubMed ID: 20585342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.